A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis
NCT02693210
Completed
WA16291 is a Phase IIa "proof-of-concept" study. The primary objective of this study is to determine the safety and efficacy of rituximab (a B cell depleting chimeric monoclonal antibody) used either as monotherapy or in combination with methotrexate or cyclophosphamide in participants with rheumatoid arthritis who have failed prior Disease Modifying Anti-Rheumatic Drug (DMARD) therapy and currently have an inadequate clinical response to methotrexate.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
10/29/2016
Locations: Not set, Darlinghurst, Not set +32 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Multicenter Uveitis Steroid Treatment (MUST) Trial
NCT00132691
Completed
The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
10/13/2016
Locations: Jacobs Retina Center, UCSD, La Jolla, California +22 locations
Conditions: Uveitis
Register for Updates
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
NCT00021255
Completed
Primary objective: * Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin. Secondary objective: * Compare overall survival of participants treated with these regimens. * Compare the toxic effects (including cardiac) of these regi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
09/26/2016
Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey +41 locations
Conditions: Breast Neoplasms
Register for Updates
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
NCT01324596
Completed
The aims of this study are: * To evaluate the benefits of the addition of bortezomib to standard rituximab with cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy in Diffuse Large B-cell Lymphoma (DLBCL). * To determine whether molecular phenotype effects the benefits derived from the addition of bortezomib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2016
Locations: Kantonsspital Aarau, Aarau, Not set +108 locations
Conditions: Lymphoma, Large B-Cell, Diffuse
Register for Updates
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
NCT00455533
Completed
The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early stage breast cancer. In addition the study will verify predefined biomarkers as well as discover new biomarkers that could identify patients who are more likely to respond to ixabepilone than standard paclitaxel based therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/25/2016
Locations: Comprehensive Cancer Center, Palm Springs, California +49 locations
Conditions: Breast Cancer
Register for Updates
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
NCT00409188
Completed
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2015
Locations: Saint Edward Mercy Medical Center, Fort Smith, Arkansas +294 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
NCT00915408
Completed
The purpose of this study is to determine the maximum tolerated dose (MTD) and to evaluate the safety of cyclophosphamide when given on days 1 and 8 in a 28 day cycle in doses starting at 300mg ranging to 700mg in combination with Lenalidomide (Revlimid®) plus dexamethasone in patients who present with relapsed or refractory myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2015
Locations: King's College Hospital NHS Foundation Trust, London, Not set +1 locations
Conditions: Multiple Myeloma
Register for Updates
A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients
NCT01444118
Terminated
The vaccine contains humanized recombinant antigen (Epithelial Growth Factor) and an adjuvant. The antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation. As a result, binding to its target EGF-Receptor is prevented. Blocking of EGF-Receptor is preventing activation and stimulation of proliferation of tumour cell. A Phase III clinical trial on the EGF vaccine is ongoing in Cuba. The result from previous studies demonstrated positive corre... Read More
Gender:
ALL
Ages:
Between 20 years and 65 years
Trial Updated:
07/20/2015
Locations: Aberdeen Royal Infirmary, Aberdeen, Not set
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
NCT02310997
Terminated
This trial is looking at using umbilical cord blood from unrelated donors after high dose chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS). The trial is for babies over 4 weeks old, children, and adults up to the age of 45.
Gender:
ALL
Ages:
Between 28 days and 45 years
Trial Updated:
05/26/2015
Locations: University College London Hospital, London, Greater London +11 locations
Conditions: Leukaemia, Lymphoma, Other Haematological Diseases
Register for Updates
Pilot Study of Unrelated Cord Blood Transplantation
NCT00916045
Terminated
The purpose of this study is to determine the safety and feasibility of unrelated double and single cord blood transplantation in patients with haematological malignancies using reduced-intensity or myeloablative conditioning regimens.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/10/2015
Locations: King's College Hosptial NHS Foundation Trust, London, Not set
Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Leukemia, Lymphoblastic, Acute, Lymphoma, Non-Hodgkin, Hodgkin Disease, Chronic Lymphocytic Leukemia
Register for Updates
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
NCT00908232
Completed
The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4 initial cycles of treatment with VD. Multiple myeloma is the second most common cancer of the blood. Bortezomib disrupts the life cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2015
Locations: Not set, Bordeaux, Not set +42 locations
Conditions: Multiple Myeloma
Register for Updates
Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
NCT00666484
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of combination chemotherapy is more effective for Hodgkin lymphoma. PURPOSE: This phase II trial is studying the side effects of three different regimens of combination chemotherapy and to see how well they work in treating younger patients with Hodgkin lymphoma.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
12/03/2014
Locations: Leeds Cancer Centre at St. James's University Hospital, Leeds, England +4 locations
Conditions: Lymphoma, Neurotoxicity
Register for Updates